Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Bethesda, Maryland

Cancer biologic therapy trials in Bethesda, MD

35 cancer biologic therapy studies are recruiting participants at sites in Bethesda as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Bethesda at a glance

  • 35 studies are recruiting at a site in Bethesda.
  • By phase: Phase 1 (3), Phase 1/2 (5), Phase 2 (13), Phase 3 (13), Phase 4 (1).
  • By sponsor: government (24), industry (8), university, hospital or other (3).
  • By research area: Lymphoma (19), Breast Cancer (7), Lung Cancer (4), Melanoma (2), Prostate Cancer (2), Pancreatic Cancer (1).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Bethesda

Basic details from each study's public record (the 30 most recently updated of 35). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    National Institutes of Health Clinical Center · Walter Reed National Military Medical Center
    Registry record
    NCT05564377 · updated
  2. Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

    • Phase 2
    • Ages 18 to 72
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT01174121 · updated
  3. Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

    • Phase 2
    • Ages 18 to 72
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT03412877 · updated
  4. Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

    • Phase 1/2
    • Ages 18 to 72
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT02830724 · updated
  5. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Walter Reed National Military Medical Center
    Registry record
    NCT06876714 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Bethesda, MD on ClinicalTrials.gov.

Lung cancer studies recruiting in Bethesda

  1. Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

    • Phase 1
    • Ages 18 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT06885697 · updated
  2. T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

    • Phase 2
    • Ages 18 to 72
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT02133196 · updated
  3. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Maryland Oncology Hematology, P.A.
    Registry record
    NCT07222566 · updated
  4. A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT06868277 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Bethesda, MD on ClinicalTrials.gov.

Prostate cancer studies recruiting in Bethesda

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT03866382 · updated
  2. Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

    • Phase 2
    • Ages 18 to 120
    • Male participants
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT07574541 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Bethesda, MD on ClinicalTrials.gov.

Melanoma studies recruiting in Bethesda

  1. Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

    • Phase 3
    • Ages 18 to 70
    • All sexes
    Sponsor
    Iovance Biotherapeutics, Inc.
    Study site
    National Cancer Institute
    Registry record
    NCT05727904 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Bethesda, MD on ClinicalTrials.gov.

Lymphoma studies recruiting in Bethesda

  1. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Walter Reed National Military Medical Center
    Registry record
    NCT06337318 · updated
  2. Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 1
    • Ages 18 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT07572136 · updated
  3. Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT04002947 · updated
  4. A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Center for Cancer and Blood Disorders ( Site 5439)
    Registry record
    NCT05947851 · updated
  5. Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

    • Phase 2
    • Ages 12 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT03258567 · updated
  6. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    American Oncology Partners, P.A. ( Site 0185)
    Registry record
    NCT06717347 · updated
  7. Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

    • Phase 1/2
    • Ages 18 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT03223610 · updated
  8. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Walter Reed National Military Medical Center
    Registry record
    NCT04269902 · updated
  9. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Walter Reed National Military Medical Center
    Registry record
    NCT05675410 · updated
  10. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    National Institutes of Health Clinical Center · Walter Reed National Military Medical Center
    Registry record
    NCT06649812 · updated
  11. Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

    • Phase 1
    • Ages 18 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT06904066 · updated
  12. Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Allogene Therapeutics
    Study site
    The Center for Cancer and Blood Disorders
    Registry record
    NCT06500273 · updated
  13. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Walter Reed National Military Medical Center
    Registry record
    NCT06124157 · updated
  14. CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

    • Phase 1/2
    • Ages 3 to 39
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT05442515 · updated
  15. CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 3 to 65
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT07328503 · updated
  16. Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

    • Phase 1/2
    • Ages 18 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT06364423 · updated
  17. Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    CSL Behring
    Study site
    American Oncology Partners, PA dba The Center for Cancer and Blood Disorders
    Registry record
    NCT07648264 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Bethesda, MD on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Bethesda

  1. Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

    • Phase 1/2
    • Ages 18 to 72
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT03190941 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Bethesda, MD on ClinicalTrials.gov.

Ask about studies near Bethesda

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Maryland

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call